Repligen (NASDAQ: RGEN)
Repligen Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Repligen Company Info
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
News & Analysis
Why Repligen Stock Is Sinking Today
Investors appear to be anticipating an underwhelming first-quarter report from the bioprocessing company.
Why Shares of Repligen Rose This Week
The company is coming off a solid third quarter and is getting noticed by analysts.
Why Shares of Repligen Surged This Week
The bioprocessing equipment company is seeing growth prospects accelerate for its non-COVID-related revenue.
Why Repligen Corporation Stock Is Storming Higher Today
Repligen's strong second-quarter results are a hit with investors.
Why Repligen Is Up More Than 10% Today
A stronger-than-expected earnings report calls months of the stock's weakness into question.
2 Reasons to Buy Repligen, and 1 Reason to Sell
Management has executed its strategy well, but a potential risk is looming.
2 Top Biotech Stocks to Buy for the Long Haul
Repligen and Exact Sciences have a proven track record with significant opportunities for continued growth.
2 Healthcare Stocks That Could Help Set You Up for Life
These two companies offer under-the-radar ways to invest in the healthcare space.
Valuation
Earnings Transcripts
Repligen Corp (RGEN) Q3 2021 Earnings Call Transcript
RGEN earnings call for the period ending September 30, 2021.
Repligen Corp (RGEN) Q2 2021 Earnings Call Transcript
RGEN earnings call for the period ending June 30, 2021.
Repligen Corp (RGEN) Q1 2021 Earnings Call Transcript
RGEN earnings call for the period ending March 31, 2021.
Repligen Corp (RGEN) Q4 2020 Earnings Call Transcript
RGEN earnings call for the period ending March 31, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.